Get started
Author

Yanan Huo

Observed names: Huo Yanan, Huo, Yanan
ORCID: 0000-0002-4541-9791
Observed ORCID: 0000-0002-4541-9791
OpenAlex ID: A5061750028
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
2024 · Amitkumar Mehta, Leslie Popplewell, et al. · Blood Advances · 36
A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants
2024 · Shangchen Song, Zachary J. Madewell, et al. · Vaccine · 32
PDF
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors
2025 · Cathy Eng, Nehal J. Lakhani, et al. · Targeted Oncology · 29
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
2024 · Joseph E. Maakaron, Adam Asch, et al. · Blood Advances · 24
TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53
2016 · Yinxiang Lv, Huo Yanan, et al. · Drug Design Development and Therapy · 17
PDF
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.
2026 · Kevin Kalinsky, Peter Schmid, et al. · Journal of Clinical Oncology · 3
Retinal capillary hemangioma associated with renal cell cancer in von Hipple-Lindau disease
2005 · Yanan Huo, Ping Wang, et al. · Shiyong zhongliu zazhi
Works count: 9
Citation count: 141
H-index: 5
I10-index: 5
Year
Topic
Type